

OncoTherapy Science, Inc.

June 6, 2016

Publication of a paper describing neoantigen-specific T-cell receptor-engineered
T cell therapy in mice

An article that described genetically-engineered T cell therapy by introduction of a neoantigen-specific T-cell receptor (TCR) has been published in Clinical Cancer Research by a research group of Dr. Matthias Leisegang, Prof. Hans Schreiber and our collaborators in The University of Chicago, Dr. Poh Yin Yew (her present address is at OncoTherapy Science, Inc. (OTS)) and Prof. Yusuke Nakamura. This article reported T cell therapy with TCR targeting a cancer-specific point mutation can eradicate large established tumors. OTS is promoting TCR analysis business and developing "Neoantigen-Dendritic Cells vaccine therapy. OTS will further accelerate this business and contribute to cancer precision medicine.

The paper was published on line in the journal.

<http://clincancerres.aacrjournals.org/content/22/11/2734.abstract>